AUTHOR=Poulakou Garyfallia , Royer Pierre-Joseph , Evgeniev Nikolay , Evanno Gwénaëlle , Shneiker Françoise , Marcelin Anne-Geneviève , Vanhove Bernard , Duvaux Odile , Marot Stéphane , Calvez Vincent 

TITLE=Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1330178

DOI=10.3389/fimmu.2024.1330178

ISSN=1664-3224

ABSTRACT=III randomized placebo-controlled clinical trial including 279 patients hospitalized or not, with mild to moderate COVID19 (7-point ordinal WHO score at 2, 3 or 4 at randomization), treatment with XAV-19 did accelerate significantly recovery defined by a reduction of 1-point or more of the 7-point ordinal scale. Strengths of XAV-19 are its affordability and its activity against SARS-CoV-2 variants. Next trials should confirm the therapeutic interest of XAV-19 for high-risk patients with mild to moderate COVID-19.